The ßAir bio-artificial pancreas, developed by Israel’s Beta-O2, was recently implanted in the first of eight diabetes patients in Sweden as part of a $1 million pilot human study on this groundbreaking treatment and potential cure for type 1 diabetes (T1D).
Chairman of the Board Dan Gelvan tells ISRAEL21c that the advanced implantable system is science-fiction-come-true for people with T1D, an autoimmune disorder — also known as insulin-dependent or juvenile diabetes – in which the immune system destroys the insulin-producing islet cells of the pancreas.
T1D patients (about three million people in the United States alone) must monitor their glucose and take insulin daily to do the essential job of converting sugar, starches and other food into energy – a task normally handled by about two grams of islet cells.
“Imagine if those with type 1 diabetes no longer had to worry about insulin injections or glucose levels. They could eat what they wanted, exercise as they wished and need not measure every step they took,” says Gelvan, also managing director of life sciences at Aurum Ventures, the company’s lead investor. “This is the future that Beta-O2 envisions ßAir will help to create.”
Pursuant to Title 17 U.S.C. 107, other copyrighted work is provided for educational purposes, research, critical comment, or debate without profit or payment. If you wish to use copyrighted material from this site for your own purposes beyond the 'fair use' exception, you must obtain permission from the copyright owner. Views are those of authors and not necessarily those of Canada Free Press. Content is Copyright 1997-2017 the individual authors. Site Copyright 1997-2017 Canada Free Press.Com Privacy Statement